Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing pattern
阅37转0刚刚Mechanism of action, indications and adverse effects of: etanercept, infliximab and adalimumab | CME
阅372转2刚刚CCFA: Biologic Therapies
阅46转0刚刚Enbrel vs. Remicade vs. Humira: Which Anti
阅98转0刚刚Rheumatoid Arthritis Market Will Grow Moderately
阅34转0刚刚Research and Markets: Brand Leaders in Rheumatoid Arthritis to Lose Market Share, Predict Rheumatolo
阅24转0刚刚The Rheumatoid Arthritis Drug Market Will Experience Modest Growth as Sales Increase from $11.1 Bill
阅26转0刚刚类风湿关节炎生物制剂治疗的新进展
阅1847转9刚刚TNF inhibitor therapy for rheumatoid arthritis (Review)
阅56转0刚刚共刺激分子受体CTLA
阅1515转8刚刚生物类抗类风湿性关节炎药物市场提速 数据与行业分析 | 39康复网 | 医源世界
阅129转1刚刚益赛普的空间：类克、益赛普和美罗华：生物制剂成为风湿疾病治疗主流药物
阅1421转12刚刚FirstWord Lists – Pharma's 50 biggest selling drugs: AbbVie's Humira joins the $10 billion club
阅74转0刚刚AbbVie's Humira turns in 18% surge in sales
阅35转0刚刚TNF
阅69转0刚刚2013年美国市场最畅销药物排行榜
阅1312转1刚刚Orencia Reviews
阅81转2刚刚Targeting Interleukin
阅35转0刚刚QIAGEN
阅112转1刚刚Rheumatoid Arthritis Symptoms, Causes, Treatment
阅46转0刚刚
-
设计心理学2：与复杂共处
